Shots:

•  The P-III study involves assessing Cosentyx (secukinumab- 150mg & 300mg) in 543 patients with moderate to severe plaque psoriasis in China
• The P-III study results: PASI 75 & PASI 90 (97.7% & 80.9%) @12 wks. @300mg; PASI 90 (87%) @16wks. @300mg; PASI 75 & PASI 90 (87.8% & 66.4%) @12wks @150mg. The results presented at the American Academy of Dermatology (AAD) Annual Meeting
• Cosentyx (secukinumab) is a mAb targeting IL-17A responsible for inflammation and development of psoriatic diseases and has approved in more than 80 countries including EU & the US

Ref: Novartis | Image: Business Insider